tetano
Editor, Senior Moderator
J Clin Med
. 2023 Mar 4;12(5):2038.
doi: 10.3390/jcm12052038.
COVID-19 and the Response to Antiplatelet Therapy
Tomáš Bolek[SUP] 1 [/SUP], Matej Samoš[SUP] 1 [/SUP], Jakub Jurica[SUP] 1 [/SUP], Lucia Stančiaková[SUP] 2 [/SUP], Martin Jozef Péč[SUP] 1 [/SUP], Ingrid Škorňová[SUP] 2 [/SUP], Peter Galajda[SUP] 1 [/SUP], Ján Staško[SUP] 2 [/SUP], Marián Mokáň[SUP] 1 [/SUP], Peter Kubisz[SUP] 2 [/SUP]
Affiliations
Abstract
The coronavirus SARS-CoV2 disease (COVID-19) is connected with significant morbidity and mortality (3.4%), disorders in hemostasis, including coagulopathy, activation of platelets, vascular injury, and changes in fibrinolysis, which may be responsible for an increased risk of thromboembolism. Many studies demonstrated relatively high rates of venous and arterial thrombosis related to COVID-19. The incidence of arterial thrombosis in severe/critically ill intensive care unit-admitted COVID-19 patients appears to be around 1%. There are several ways for the activation of platelets and coagulation that may lead to the formation of thrombi, so it is challenging to make a decision about optimal antithrombotic strategy in patients with COVID-19. This article reviews the current knowledge about the role of antiplatelet therapy in patients with COVID-19.
Keywords: COVID-19; antiplatelet therapy; arterial thrombosis; aspirin.
. 2023 Mar 4;12(5):2038.
doi: 10.3390/jcm12052038.
COVID-19 and the Response to Antiplatelet Therapy
Tomáš Bolek[SUP] 1 [/SUP], Matej Samoš[SUP] 1 [/SUP], Jakub Jurica[SUP] 1 [/SUP], Lucia Stančiaková[SUP] 2 [/SUP], Martin Jozef Péč[SUP] 1 [/SUP], Ingrid Škorňová[SUP] 2 [/SUP], Peter Galajda[SUP] 1 [/SUP], Ján Staško[SUP] 2 [/SUP], Marián Mokáň[SUP] 1 [/SUP], Peter Kubisz[SUP] 2 [/SUP]
Affiliations
- PMID: 36902825
- DOI: 10.3390/jcm12052038
Abstract
The coronavirus SARS-CoV2 disease (COVID-19) is connected with significant morbidity and mortality (3.4%), disorders in hemostasis, including coagulopathy, activation of platelets, vascular injury, and changes in fibrinolysis, which may be responsible for an increased risk of thromboembolism. Many studies demonstrated relatively high rates of venous and arterial thrombosis related to COVID-19. The incidence of arterial thrombosis in severe/critically ill intensive care unit-admitted COVID-19 patients appears to be around 1%. There are several ways for the activation of platelets and coagulation that may lead to the formation of thrombi, so it is challenging to make a decision about optimal antithrombotic strategy in patients with COVID-19. This article reviews the current knowledge about the role of antiplatelet therapy in patients with COVID-19.
Keywords: COVID-19; antiplatelet therapy; arterial thrombosis; aspirin.